Filgotinib effective in refractory RA
Expert calls for head-to-head comparisons with other therapies
1st August 2019
The JAK1 inhibitor filgotinib improves outcomes in patients with active rheumatoid arthritis refractory to disease-modifying anti-rheumatic drug (DMARD) therapy, a clinical trial shows.